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Abstract
Background: The progression of all cancers is characterized by increased-cell proliferation and
decreased-apoptosis. The androgen-independent prostate cancer (AIPC) is the terminal stage of
the disease. Many chemokines and cytokines are suspects to cause this increased tumor cell survival
that ultimately leads to resistance to therapy and demise of the host. The AIPC cells, but not
androgen-responsive cells, constitutively express abundant amount of the pro-inflammatory
chemokine, Interleukin-8 (IL-8). The mechanism of IL-8 mediated survival and therapeutic
resistance in AIPC cells is unclear at present. The purpose of this report is to show the pervasive
role of IL-8 in malignant progression of androgen-independent prostate cancer (AIPC) and to
provide a potential new therapeutic avenue, using RNA interference.
Results: The functional consequence of IL-8 depletion in AIPC cells was investigated by RNA
interference in two IL-8 secreting AIPC cell lines, PC-3 and DU145. The non-IL-8 secreting LNCaP
and LAPC-4 cells served as controls. Cells were transfected with RISC-free siRNA (control) or
validated-pool of IL-8 siRNA. Transfection with 50 nM IL-8 siRNA caused >95% depletion of IL-8
mRNA and >92% decrease in IL-8 protein. This reduction in IL-8 led to cell cycle arrest at G1/S
boundary and decreases in cell cycle-regulated proteins: Cyclin D1 and Cyclin B1 (both decreased
>50%) and inhibition of ERK1/2 activity by >50%. Further, the spontaneous apoptosis was increased
by >43% in IL-8 depleted cells, evidenced by increases in caspase-9 activation and cleaved-PARP.
IL-8 depletion caused significant decreases in anti-apoptotic proteins, BCL-2, BCL-xL due to
decrease in both mRNA and post-translational stability, and increased levels of pro-apoptotic BAX
and BAD proteins. More significantly, depletion of intracellular IL-8 increased the cytotoxic activity
of multiple chemotherapeutic drugs. Specifically, the cytotoxicity of Docetaxel, Staurosporine and
Rapamycin increased significantly (>40% at IC50 dose) in IL-8 depleted cells as compared to that in
C-siRNA transfected cells.
Conclusion: These results show the pervasive role of IL-8 in promoting tumor cell survival, and
resistance to cytotoxic drugs, regardless of the cytotoxic mechanism of antiproliferative drugs, and
point to potential therapeutic significance of IL-8 depletion in men with AIPC.
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Prostate cancer ranks second in incidence and mortality
among all cancers in men in the United States [1]. The cas-
tration resistant, androgen-independent prostate cancer
(AIPC) accounts for most mortalities from this disease.
The AIPC is also associated with poor response to chemo-
therapy drugs, and therefore, high mortality with an esti-
mated life span of 2–4 years [2,3]. Many factors contribute
to this state of the disease, including multiple survival
mechanisms, resistance to apoptosis and development of
resistance to therapeutic drugs. The present investigation
is to understand whether these are contributed by the abil-
ity of AIPC cells to chemokines such as Interleukin-8 (IL-
8) in a paracrine or autocrine fashion.
IL-8 is a multifunctional chemokine, involved in inflam-
mation mediated neutrophil infiltration and chemotaxis
[4]. A member of the Cysteine-X-Cysteine (CXC) motif
chemokines, IL-8 is one of the most promiscuous media-
tors of immune and cellular functions, including motility,
invasion and activation of survival and proliferative path-
ways in cells of mesenchymal lineage and in aggressive
tumor cells [5,6]. The up-regulation of IL-8 in various
pathologies is attributed to the structure of IL-8 promoter.
The IL-8 promoter binds to Nuclear Factor kappa B (NF-
kB), AP-1 and other inflammation related enhancers [7].
Expression of IL-8 in tumor cells may also be associated
with constitutive activation of inflammatory pathway,
such as that initiated by activation of NF-kB, AP-1 and
hypoxia inducible factor-1α in some tumor cells [8,9].
Since IL-8 is a secreted protein, conditions prevailing in
the tumor microenvironment, such as infiltrating mono-
cytes and lymphocytes, may further increase the influence
of IL-8 in such tumors [10-12].
IL-8 binds to two cell surface G-protein coupled receptors
(GPCR), IL-8 receptor A and IL-8 receptor B or CXCR1 and
CXCR2, respectively. IL-8 receptors, unlike IL-8, are con-
stitutively expressed in both mesenchymal and epithelial
cells [13] and CXCR2 binds multiple other ligands
[14,15]. IL-8 induced cellular functions are mediated
through the activation of these two receptors. Studies have
shown that disease progression and metastasis may be
associated with over-expression of IL-8 [6,16]. However,
the mechanism by which IL-8 promotes various pro-sur-
vival and anti-apoptotic functions is unclear at present.
AIPC cells synthesize and secrete IL-8 but not normal pro-
static epithelial cells, primary tumors and in androgen-
dependent/responsive prostate cancer cell lines [17,18].
Several investigators have reported the generation of
androgen-independent cell clones that are not only capa-
ble of growing in the absence of androgen, but also secrete
IL-8 [19,20]. We reported previously, that forced expres-
sion of IL-8 in androgen-responsive cells leads to andro-
gen-independent cell growth and up regulation of several
key attributes of invasion and metastasis [21]. In addition,
over expression of IL-8 in IL-8 secreting AIPC cells causes
them to grow as more aggressive and angiogenic tumors
in vivo [22,23]. However, the mechanism of growth
advantage rendered by constitutive IL-8 production, with-
out over expression, is not delineated. For example, earlier
studies attributed most of the tumor growth promoting
activities of IL-8 to its effect on angiogenesis, not the sur-
vival [22,23]. We hypothesized that IL-8 is a survival fac-
tor that not only promotes proliferation pathway, but also
controls apoptotic pathway, due to its interaction with
protein kinase-B (AKT) and NF-kB. The focus of the
present report is to demonstrate the contribution of IL-8
in prostate cancer cell-survival, invasion and resistance to
chemotherapeutic drugs in two AIPC cell lines, PC-3 and
DU145 by RNA interference.
Results
Effect of siRNA directed IL-8 silencing in AIPC cells
Transfection of PC-3 and DU145 cells with Smartpool
siRNA, directed against IL-8 mRNA reduced the expres-
sion of IL-8 mRNA in a dose-dependent manner (50–
95%) at a concentration range of 25 nM to 100 nM. How-
ever, non-target, scrambled sequence-siRNA (C-siRNA)
and IL-8 siRNA, both, showed off-target toxicity at ≥ 100
nM. At 50 nM, C-siRNA did not cause an alteration in cell
viability, or IL-8 mRNA, but transfection with 50 nM IL-8
siRNA caused 98% and 92% decrease in IL-8 mRNA levels
in PC-3 and DU145 cells, respectively (Fig. 1A &1C). Fur-
thermore, we observed mean decreases of 92% and 85%
in secreted IL-8 levels at 72 h after transfection in PC-3
and DU-145 cells, respectively (Fig. 1B &1D).
IL-8 depletion causes inhibition of PC-3 and DU145 cells 
proliferation
Reduction of IL-8 expression by transfection with 50 nM
IL-8 siRNA caused a significant decrease in cell viability.
Decrease in cell viability was measured with an MTT
reduction assay, 48 h following transfection. Cell viability
decreased by 30 ± 5.2% in PC-3 and 28 ± 4.7% in DU145
cells, respectively, to that of mock transfection. As shown
in Fig. 2A, C-siRNA had no significant effect on cell prolif-
eration in either cell lines. Furthermore, IL-8 siRNA had
no effect on the proliferation of androgen-responsive, IL-
8 non-secreting LNCaP cells (data not shown). Since
siRNA-mediated gene silencing lasts two to four days in
cell culture, we did not use clonogenic survival assays (col-
ony assay) or generate cell growth curves to determine the
long-term growth inhibition. To distinguish between
alteration in cell proliferation and cell viability, we usedPage 2 of 15
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provided more analytical details of cell cycle distribution
of transfected cell cultures.
IL-8 depletion affects the cell cycle distribution
As shown in Fig. 2B, IL-8 depletion by siRNA transfection
caused an arrest of PC-3 cells in G1 phase of cell cycle, and
prevented their entry into S-and G2/M phase. The fraction
of cells in G0/G1 phase in IL-8 siRNA transfected cells was
significantly higher (85%) compared to that of C-siRNA
transfectants (68%) (Table insert in Fig. 2B). Similar cell
cycle phase analysis in DU145 cells also showed the G1
phase arrest when transfected with IL-8 siRNA (data not
shown).
We next analyzed the levels of key molecules that control
the progression of cells from G1 to S-phase of the cell
cycle. The expression of Cyclin D1 and Cyclin B1
decreased significantly in IL-8 depleted cells. We detected
decreased levels of Cyclin D1 and Cyclin B1 in both PC-3
and DU145 cells (Fig. 2C). Furthermore, growth factor
induced increase in Cyclin D1 level was modest in IL-8
depleted cells, when compared to those with C-siRNA
transfected cells (Fig. 2D). As shown in Fig. 2D, external
Depletion of IL-8 in PC-3 and DU145 cells by siRNA transfectionFigure 1
Depletion of IL-8 in PC-3 and DU145 cells by siRNA transfection: A and C: Decrease in IL-8 mRNA levels: Cells 
were transfected with 50 nM of control-siRNA (C-siRNA) or Smartpool siRNA against IL-8 (IL-8 siRNA). Total RNA was 
extracted 48 h after transfection to determine the levels of IL-8 mRNA by Q-RT PCR, as described in Materials and Methods 
(text). Each RNA sample was also simultaneously subjected to Q-RT PCR to determine the level of GAPDH mRNA for nor-
malization. The threshold cycle (Ct) of each reaction generated by the iCycler program (Bio-Rad Inc.) was used to determine 
the relative mRNA levels in the test samples, using the formula: Fold Difference (FD) = 1-(2ΔCt), where, ΔCt = (Cttest RNA - 
CtGAPDHRNA). Final value of IL-8 mRNA, relative to that of GAPDH was expressed as: 1/FD × 100 to obtain integer values, in 
arbitrary units. B and D: Levels of IL-8 protein secreted into the culture medium, 48 h after transfection. IL-8 levels 
were measured using an ELISA kit. Levels are expressed as % of untreated control. Untreated PC-3 cells secreted ~ 60 ng IL-8/
106 PC-3 cells/24 h and ~ 10 ng IL-8/106 DU145 cells/24 h.Page 3 of 15
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siRNA transfectants within 30 min and stayed high for 60
min, however, it increased only ~30% in IL-8siRNA trans-
fected cells. However, in contrast to IL-8 siRNA transfect-
ants, C-siRNA transfectants showed increased Cyclin D1
expression after IGF-1 addition.
External addition of IL-8 rescues IL-8 siRNA mediated 
growth arrest
Using levels of Cyclin D1 as readout, we examined
whether IL-8siRNA mediated growth arrest is specific to
IL-8 depletion or due to events unrelated to IL-8. Since
external addition of IL-8 up regulates Cyclin D1 in PC-3
cells by increasing its translation [24], we examined
whether such treatment rescues siRNA transfected cells.
We treated C-siRNA or IL-8siRNA transfected PC-3 cells
with IL-8 (25 ng/ml) for up to one hour and determined
the level of Cyclin D1 by western blotting. As shown in
Fig. 3A, external addition of IL-8 in C-siRNA transfected
PC-3 cells (in which cells continue to make IL-8) did not
induce significant increase in Cyclin D1. However, exter-
nal addition of IL-8, to a PC-3 cell cultures at 48 h after
transfecting with IL-8 siRNA increased the Cyclin D1 level
significantly, in a time-dependent manner (Fig. 3A(ii)). In
addition, we observed that external addition of IL-8
increases Cyclin D1 level in cells that do not constitutively
produce IL-8, such as LNCaP (Fig. 3B(i) and 3B(ii)) and
LAPC-4 (Fig. 3C(i)). These results corroborate the specifi-
city of IL-8 siRNA and both autocrine and paracrine func-
tion of IL-8 in stimulating cell cycle progression via Cyclin
D1 accumulation. The observation that elevated Cyclin
D1 level in IL-8 producing PC-3 cells but lack of stimula-
IL-8 depletion in AIPC cells causes decrease in cell proliferation and cell cycle arrestFigur  2
IL-8 depletion in AIPC cells causes decrease in cell proliferation and cell cycle arrest: (A). Cell viability was meas-
ured using the MTT assay, 48 h after transfection. Triplicate wells were used for each measurement, experiment repeated 
three times per cell line. Error bars: mean ± s.e.m, n = 3. (B). Cell cycle arrest at G1/S boundary. Percent of cells in each 
of the three cell cycle phase was determined by flow cytometry, 48 h after siRNA transfection. Results shown are from one 
transfection experiment, similar results were obtained in two separate determinations. (C). Levels of Cyclin D1 and Cyclin 
B1 expression: Detected by immunoblotting, as described in the text. β-actin levels, as shown, were used to normalize the 
protein levels of Cyclin D1 and Cyclin B1. The decrease in the levels of Cyclin D1 by IL-8 depletion was 68% in PC-3 and 52% 
in DU145 cells. The decrease in Cyclin B1 level was 73% in PC-3 and 41% in DU145, as determined by densitometry measure-
ment of band intensities and normalized to β-actin levels. D. IL-8 siRNA transfection decreases growth factor (IGF-1) 
mediated mitogenic stimulation. Cyclin D1 in cell lysates, prepared from PC-3 cells stimulated with IGF-1, was detected 
by western blotting. Levels of Cyclin D1 were normalized to β-actin (Actin) levels detected by re-probing the same blots.Page 4 of 15
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External IL-8 restores the functions of IL-8 depleted by siRNA transfectionFigure 3
External IL-8 restores the functions of IL-8 depleted by siRNA transfection: Effect of addition of recombinant human 
IL-8 (rhIL-8) on Cyclin D1 level was determined by western blotting. PC-3 cells transfected with 50 nM C-siRNA or IL-8 
siRNA and cultured in complete medium for 48 h were stimulated with rhIL-8 (25 ng/ml) and harvested by SDS-sample buffer 
at 0, 15, 30 and 60 min, and probed for Cyclin D1 and β-actin (A (i)). Expression of Cyclin D1 relative to β-actin in PC-
3 cells: Cyclin D1 was quantified by densitometry and expressed as a ratio of the band intensity with respect to β-actin (A (ii)). 
Note that Cyclin D1 level rose significantly in cultures depleted with IL-8 but supplemented with external IL-8. B. IL-8 stimu-
lates Cyclin D1 in LNCaP cells. LNCaP cells cultured in complete medium for 48 h were stimulated with rhIL-8 before har-
vesting and determining Cyclin D1 level, as described for A. C. Cyclin D1 in IL-8 stimulated LAPC4 and LAPC4IL-8 
cells. (i). The experimental conditions to determine Cyclin D1 were identical to the one used in B, except that LAPC4IL-8 
cells were used that constitutively produce IL-8 (8 ng/106 cells/24 h) [18]. Note that, while significant increase in Cylcin D1 is 
observed in LAPC-4 cultures stimulated with IL-8, the increase in Cyclin D1 level was negligible in LAPC4-IL-8 cells (C(ii)). D. 
Phosphorylated ERK1/2 levels are lower in IL-8 depleted cells: Levels were determined by an ELISA from cell lysates 
prepared from EGF-stimulated PC-3 cells with C-siRNA or IL-8 siRNA transfection. Error bars indicated are Mean ± SD from 
pooled data of two independent determination with triplicate samples. Significance of the observation was tested using Stu-
dent's t-test as described in Methods. (* indicates p = 0.05, determined using t-test as described in the Methods.).
Molecular Cancer 2009, 8:57 http://www.molecular-cancer.com/content/8/1/57tion of Cyclin D1 translation following external IL-8 addi-
tion in these cells prompted us to inquire whether
constitutive induction of intracellular IL-8 by forced
expression renders these cells insensitive to paracrine
stimulation with IL-8. Indeed, as shown in Fig. 3C(i, ii) we
found high level of Cyclin D1 in LAPC4-IL-8 cells that
constitutively produce IL-8 due to constitutive expression
of IL-8sense cDNA transfection, as described before [21].
Next, we investigated whether IL-8 depletion alters the
mitogenic signaling cascade. Specifically, we determined
whether IL-8 depletion leads to an inhibition or attenua-
tion of MAP kinases, such as ERK1/2. MAP kinase activity
in IL-8 depleted cells was about 50% of the C-siRNA trans-
fected cells, however, following addition of EGF (20 nM)
there was a rapid increase in MAP kinase activity in both
C-siRNA and IL-8 siRNA transfected cells (Fig. 3D).
Although, the rate of increase in IL-8 siRNA transfected
cells was comparable to that of C-siRNA transfected cells,
the absolute level was only ~40% of that of C-siRNA trans-
fectants. These results demonstrate that IL-8 depletion can
potentially cause attenuation of growth factor signaling in
tumor tissue.
IL-8 siRNA down regulates key factors that control survival 
and metastatic pathway
We examined two key factors that are involved in survival
and metastatic pathway, protein kinase B (AKT) and NF-
kB activities [25,26]. As shown in Fig. 4A, we observed a
significant reduction in phosphorylated form of AKT in
IL-8 depleted cells as compared to the cells transfected
with C-siRNA alone. The decrease in phospho-AKT to
total AKT was more than 2-fold in IL-8siRNA transfect-
ants. Phospho-AKT level was decreased by 60% in PC-3
cells and 75% in DU145 cells transfected with IL-8 siRNA
(Fig. 4A). Furthermore, we found a significant decrease
(38.5% ± 4.8%) in the endogenous NFkB activity in IL-8
depleted cells (Fig. 4B), assayed using an NF-kB reporter
construct [21].
IL-8 depletion reduced VEGF expression
Several investigators have reported a close link between
tumor angiogenesis and IL-8 [[10,11,22], and [23]]. Since
IL-8 and VEGF are implicated in increasing angiogenic
potential in PC-3 cells [23], we investigated whether IL-8
depletion reduces the expression of angiogenic factors,
such as the VEGF. As shown in Fig. 4C, IL-8 depletion by
siRNA transfection significantly reduced both mRNA
(70%) and protein (<33%) levels of VEGF in both PC-3
and DU145 cells transfected with IL-8siRNA.
IL-8 depletion causes a decrease in tumor cell chemotactic 
motility and chemo-invasive potential
IL-8 affects both motility and invasive potential when
added externally at high concentration (25 nM) [21], the
role of autocrine IL-8 in tumor cell motility and invasive
potential in prostate cancer is not been reported until
now. More importantly, although several studies have
demonstrated its endocrine/paracrine activities, whether
autocrine IL-8 signaling (i.e., signaling due to the intracel-
lular production of IL-8), is sufficient to cause significant
motility and invasive activity, the two critical determi-
nants of metastatic phenotype is not tested until now. As
illustrated in Fig. 4D, IL-8 depleted cells showed a signifi-
cant decrease in both chemotactic motility and chemoin-
vasion. The decrease in chemotactic motility in PC-3 cell
toward 10% fetal bovine serum (40% ± 5.5%) was com-
parable to that of chemo-invasive activity (44.7% ±
3.7%). In DU145 cells, decreases of 36.3% ± 2.7% inva-
sion versus 42.7% ± 4.4% in motility was observed when
transfected with IL-8 siRNA.
Enhancement of apoptosis with endogenous IL-8 depletion
Since we found IL-8 depletion decreases cell survival, we
investigated whether this is due to an increase in sponta-
neous apoptosis following siRNA transfection. The cell
lysates of PC-3 and DU145 cells, prepared 48 h after trans-
fection with IL-8 siRNA or C-siRNA, were analyzed for
apoptosis markers by western blotting. We analyzed the
levels (85-kDA fragment) of cleaved Poly-(ADP Ribose)
polymerase (PARP) protein [27]. PARP is cleaved by acti-
vated caspase-3 [28]. Caspase-3 is cleaved by Caspase-9
due to mitochondrial permeability increase and the
release of Cytochrome C [29]. Since cleaved PARP is the
signature event in apoptosis, we rationalized that analysis
of cleaved PARP level should indicate spontaneous apop-
tosis in IL-8 siRNA transfected cells. Indeed, IL-8 siRNA
transfected cells showed increased Caspase-9 activity and
increased PARP cleavage (Fig. 5A). These experiments sug-
gest that in IL-8 expressing cells, IL-8 may be suppressing
spontaneous apoptosis, by yet unknown mechanism. In
addition, these events are also linked to the levels of BCL-
2, BCL-xL, BAX and BAD proteins [30]. As shown in Fig.
5A, we found significant increase in both caspase-9 activa-
tion and increased PARP levels in IL-8 siRNA transfectants
when assayed 48 h after transfection.
IL-8 depletion causes alteration in apoptosis-related 
proteins
Earlier reports have shown that apoptosis suppressor pro-
teins, BCL-2 and BCL-xL are constitutively higher in IL-8
expressing PC-3 and DU145 cells, compared to that in IL-
8 non-secreting LNCaP or LAPC4 cells [30]. As shown in
Fig. 5A and Fig. 5B, western blot analysis showed that the
transient transfection with IL-8 siRNA resulted in signifi-
cant reduction of BCL-2 protein 48 h after transfection.
Consistent with this finding in PC-3 cells, we observed
similar results in DU145 cells after IL8-siRNA transfection
(Fig. 5B). We noticed significant reduction of BCL-2 in
DU145 cells transfected with IL8 siRNA compared to thatPage 6 of 15
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expression in IL-8 siRNA and C-siRNA transfectants of PC-
3. As shown in Fig. 4A &4B, we were unable to detect BCL-
xL expression in PC-3 cells transfected with IL-8 siRNA,
although in similarly transfected DU145 cells expressed a
detectable level of BCL-xL protein.
We further tested whether reduction of BCL-2 and BCL-xL
protein expression changed the proportion of pro-apop-
totic BAX-BAD proteins [31-33]. We used the western
blotting to compare the levels of these proteins in cell
lysates of IL-8 siRNA and C-siRNA transfected cultures. As
compared to C-siRNA, IL-8 siRNA transfectants showed
Decrease in survival and angiogenic factors in IL-8 depleted AIPC cellsFigure 4
Decrease in survival and angiogenic factors in IL-8 depleted AIPC cells: (A). IL-8 depletion reduced the steady state 
levels of activated AKT (Phospho-AKT). Phospho-AKT levels were detected by western blotting in cell lysates, prepared 48 h 
following C-siRNA or IL-8 siRNA transfection of PC-3 or DU145 cells. Numbers at the bottom of the gel indicate p-AKT band 
intensity relative to that of C-siRNA transfectants, after normalizing the band intensities to that of T-AKT. (B). NFkB activ-
ity in PC-3 cells measured using a NFkB-Luciferase reporter construct co-transfected with control or IL-8 siRNA and TK 
renilla plasmid as described in the text. (C). VEGF levels in IL-8siRNA or C-siRNA transfected PC-3 and DU145 
cells. Relative levels of VEGF mRNA, 48 h after transfection, were determined by Q-RTPCR. VEGF protein levels in culture-
conditioned medium of transfected cells from 24 h-48 h, following transfection, were determined using an ELISA kit (R&D sys-
tem Inc.) * p < 0.05. D. Decrease in the invasion and motility activity of PC-3 and DU145 cells transfected with IL-
8 siRNA. Fractions of cells migrated to bottom wells either due to chemotaxis or invaded the Matrigel-coated filters were 
determined by MTT assay, as described in the text. The data shown is from a single experiment with triplicate wells, similar 
results were obtained from two independent experiments. Note the %-invaded cells is higher than that of % motility because, 
the invasion assay was terminated at 48 h and motility assay at 24 h. At 24 h, MTT assay was too insensitive to estimate of %-
invaded cells in DU145 cells. Error bars: Mean ± SD. * represents the probability (p) that the measured values presented from 
IL-8siRNA and C-siRNA transfectants are the same; p < 0.001 in all experiments (B-D).Page 7 of 15
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5B).
We analyzed whether the down-regulation of apoptosis
suppressor protein in AIPC cells is due to decrease tran-
scription or protein turnover (ubiquitylation and proteas-
omal degradation), or both. We performed Q-RTPCR
analysis of BCL-2 mRNA expression and protein turnover
analysis using 26S-proteosome inhibitor, Carbobenzoxy-
L-leucyl-L-leucyl-L-leucinal Z-LLL-CHO (MG132, 10 μM)
[21]. As shown in Fig. 5C, we found a steep decline in
BCL-2 mRNA level in IL-8 siRNA transfected cells, com-
pared to the C-siRNA transfected cells. Treatment of C-
siRNA and IL-8 siRNA transfected cells with MG132, for 6
h after 40 h following transfection, showed a slight
decrease in BCL-2 levels in MG132 treated samples, in
both control and IL-8 siRNA treated samples, indicating
the toxicity of MG132 in PC-3 cells (Fig. 5D). However,
MG132 treated samples retained higher level of BCL-2 in
IL-8 depleted cultures, compared to that in IL-8 siRNA
transfected cells, without incubation with MG132. These
results show that despite the toxicity of MG132 in PC-3
cells, IL-8 depletion causes further decrease in BCL-2 pro-
tein. Thus, IL-8 is likely to participate in both transcription
and translational control of BCL-2. Compared to the near-
total decline in BCL-2 level in IL-8 depleted cells, it
IL-8 depletion causes decrease in anti-apoptotic proteins and increase in pro-apoptotic proteins in AIPC cellsFigur  5
IL-8 depletion causes decrease in anti-apoptotic proteins and increase in pro-apoptotic proteins in AIPC cells. 
A. Depletion of IL-8 in PC-3 and (B) DU145 cells caused increased spontaneous apoptosis detected by caspase-9 activa-
tion; cleaved caspase-9 fragments, both of and 37 kDa and 35 kDa along with 39 kDa latent caspase-9 and cleaved poly(ADP-
ribose)polymerase (PARP) (85 kDa) proteins are shown. Levels of BCL-2, BCL-xL, BAX and BAD were detected by western 
blotting of cell lysates prepared 48 h after transfecting the cells with 50 nM IL-8 siRNA or C-siRNA. β-Actin level is shown to 
ascertain equal protein loading in all lanes. C. Decrease in BCL-2 level was due to decrease in mRNA level determined by 
Q-PCR. D. The decrease in BCL-2 and increase in BAX level may also be due to rapid degradation of BCL-2 protein 
that in turn resulted in increased level of BAX. Inhibition of proteasome degradation of BCL-2 by MG132 shows unchanged 
level of BCL-2 between C-siRNA transfected control and IL-8siRNA transfected cells (Lanes 3 and 4).Page 8 of 15
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Molecular Cancer 2009, 8:57 http://www.molecular-cancer.com/content/8/1/57caused, not only an increase in BAX mRNA (data not
shown), but also showed a significant increase in protein
levels (Fig. 5A).
IL-8 depletion in AIPC cells increases the chemosensitivity 
to anticancer drugs
Since IL-8 depletion decreases the activity of NF-kB, AKT,
BCL-2 and BCL-XL, we investigated whether this also
affects response to cytotoxic, anticancer drugs. We chose
docetaxel, an inhibitor of microtubule depolymerization
that blocks cells at G2/M phase [34], staurosporine, a
strong inhibitor of protein kinase C and apoptosis induc-
ing drug [35] and rapamycin, an S6-kinase inhibitor [36].
We chose these drugs as representative chemotherapeutic
drugs each with unique mechanism of action in tumor
cells. The cell cultures transfected with C-siRNA or IL-8
siRNA for 24 h were exposed to several concentrations of
each drug for the next 48 h. Cell viability was estimated in
untreated control, single treatment alone, and combined
siRNA and drug exposed cultures by MTT assay. The com-
bination of 10 nM of docetaxel and IL-8 siRNA transfec-
tion significantly enhanced cytotoxicity in PC-3 cells. We
found their survival decreased to <10% (>90% decrease in
viability) when the cultures were exposed to docetaxel 24
h after IL-8 siRNA transfection, as compared to the 28%
survival with docetaxel plus C-siRNA transfection-combi-
nation (Fig. 6A). Similarly, as illustrated in Fig. 6B, cell
viability of IL-8siRNA transfected cultures, treated with
100 nM Staurosporine, was <10% compared to >50% via-
bility of cultures transfected only with C-siRNA, indicat-
ing a 40% increase in cytotoxicity due to IL-8 knockdown.
We obtained similar results in DU145 cells treated with
the staurosporine and siRNA (Fig. 6, right panels). Fur-
ther, a significant reduction in viability also was observed
in the IL-8 siRNA transfectants treated with rapamycin.
We found >90% reduction in viability in IL-8 siRNA trans-
fected cultures treated with rapamycin compared to <45%
reduction in cell viability of C-siRNA transfected cells
treated with rapamycin. The IL-8 siRNA and C-siRNA
transfectants of DU145 cells treated with rapamycin (10
μM) for 24 hr, showed cell viability of <20% and >45%,
respectively.
Discussion
This study demonstrated the capability of siRNA in silenc-
ing IL-8 mediated autocrine-regulation of major functions
of AIPC cells. We observed that depletion of endogenous
expression of IL-8 (over 90%) by siRNA decreased PC-3
and DU145 cell proliferation, cell cycle progression, ang-
iogenic potential and up-regulated spontaneous apopto-
sis. Furthermore, since its depletion reduced the levels of
Cyclin D1 and Cyclin B significantly, we also provide the
evidence that endogenous IL-8 stimulates Cyclin D1 syn-
thesis with or without a mitogenic factor, such as IGF-1 or
exogenous IL-8 stimulation, (Fig. 2B). In addition to the
decrease in Cyclin D1 levels, we also observed a steep
decrease in the level of other nuclear proteins involved in
cell cycle progression, such as Cdk2 (data not shown), and
Cyclin B1. The phenotype of this inhibition is seen as the
cell cycle arrest at G1 to S-phase transition.
This work complements and extends the previous work
[22,23]. In earlier report, it was shown that anti-sense
cDNA mediated silencing of IL-8 in PC-3M and PC-3M-
LN4 cells, two highly metastatic variants of PC-3, caused a
reduction in tumorigenicity, angiogenesis and metastasis
[22]. The authors reported a 5–10 fold reduction in IL-8
mRNA and protein levels in cell culture studies, and ~50%
reduction in IL-8 in tumors. This compares to our finding
that siRNA mediated silencing resulted in >98% reduction
in IL-8 mRNA and 91% reduction in IL-8 protein in vitro,
which led to dramatic changes in the cellular phenotype.
Whether this reduction leads to similar anti-tumor activity
in vivo is not tested at present, since siRNA mediated gene
silencing is transient and unsuitable, at present, for testing
its efficacy in vivo on tumor growth.
MacManus CF et al., [24] reported that external addition
of IL-8 regulates Cyclin D1 synthesis at the translation
stage via S6 kinase-mediated ribosomal phosphorylation
mechanism. In addition, they also showed external addi-
tion of IL-8 causes AKT phosphorylation and activation of
mTOR pathway in PC-3 cells. As we have shown in this
report and that of others, PC-3 cells constitutively produce
significant amount of IL-8. Therefore, extracellular expo-
sure to IL-8 may not be necessary to elicit some of the IL-
8 mediated signaling. We found that exogenous addition
of IL-8 only moderately up regulated Cyclin D1 in both
PC-3 cells (Fig. 3A). However, in IL-8 depleted PC-3 cells
and in those cells that do not constitutively produce IL-8
(e.g., LNCaP and LAPC-4), external addition of IL-8 signif-
icantly up regulated Cyclin D1 (Fig. 3A, B, and 3C). Thus,
IL-8 is capable of inducing cell proliferation in both IL-8
non-producing androgen responsive CaP cells and in
AIPC cells, either by endocrine/paracrine, or by autocrine
mechanism.
PC-3 cells form rapidly growing tumors in mice, without
any external stimulation by IL-8. Autocrine secretion in
the only mechanism by which IL-8 is available to tumor
cells in xenografts. The mouse homolog of IL-8 has poor
affinity to IL-8 receptors, CXCR1 and CXCR2 in human
cells, although human IL-8 binds to murine IL-8 recep-
tors, which may be a cause of increased angiogenesis activ-
ity in xenografted PC-3 tumors [37]. However, we do find
that mitogenic signaling by IL-8 is mediated by autocrine
signaling, through binding to the cell surface receptors of
IL-8, CXCR1 and CXCR2. Interestingly, as shown in Fig.
2D, mitogenic signaling by other growth factor, such as
IGF-1 also is attenuated without the endogenous expres-Page 9 of 15
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ing may synergistically enhance other MAP kinase-
induced signals. Indeed, IL-8 stimulates and activates
EGFR phosphorylation and MAPK activation in VSV-
infected lung epithelial cells [38]. Thus, the results pre-
sented in this report clearly demonstrate that autocrine
production of IL-8 plays a significant role in the prolifera-
tion of AIPC cells such as PC-3 and DU145, and enhance
mitogen-stimulated cell cycle progression without any
extrinsic source of IL-8.
We find that most of the CaP cell lines, that express andro-
gen receptors with or without sensitivity to androgen-
induced proliferation, do not express IL-8 under normal
culture conditions. We tested this in LNCaP, LAPC-4,
22Rw21 and LNCaP-C4-2B (unpublished results). How-
ever, they do express IL-8 if stimulated by bacterial toxins
[39] or under hypoxic conditions [40], thus demonstrat-
ing the plasticity of IL-8 expression in all CaP cells. We
have shown previously that IL-8 level is increased in pri-
mary CaP tissues and is an independent predictor of bio-
chemical (PSA relapse) recurrence [41], thus
demonstrating its significance in primary tumor tissues
(in prostate). The autocrine stimulation of IL-8 may be
advantageous to proliferation, survival, motility and inva-
sion, and resistance to cytotoxic drugs, when surviving in
an ectopic environment, such as during seeding and
growth in distant organs, such as bone and lungs. The
ability to produce IL-8 in an autocrine fashion, with or
without other survival and mitogenic factors, may be a
critical determinant during initial survival and clonogenic
proliferation in mitogen-poor environment or during
total androgen-blockade. Indeed, Tso et al., [20] observed
elevation of IL-8 as one of the key factors when they
selected androgen-independent sub clones of LNCaP
cells, an androgen-responsive cell line that does not
secrete IL-8 [21].
Another significant finding of our study is that knock-
down of endogenous IL-8 expression in AIPC cells reduces
the NF-kB activity and phosphorylated-AKT level. In AIPC
cells, AKT and NF-kB are constitutively activated and are
known to exert significant effect on cell survival, resistance
to anticancer drug-induced apoptosis and metastatic
potential [41,42]. Whether constitutive activation of NF-
kB is a cause of IL-8 production or constitutive production
of IL-8 elevates NF-kB and AKT activity is not clear at
present. However, at least in PC-3 and DU145 cells, it was
recently elucidated that IL-8-CXCR2 interaction results in
increased NF-kB activity during normal and stressed (drug
or hypoxia) conditions [43]. Our results show that
indeed, without external source of IL-8, constitutive acti-
IL-8 depletion increases the cytotoxicity of chemotherapeu-tic drugs in AIPC c llsFigur  6
IL-8 depletion increases the cytotoxicity of chemo-
therapeutic drugs in AIPC cells. IL-8 siRNA or CsiRNA 
transfected PC-3 and DU145 cells were exposed to cyto-
toxic drugs, 24 h after transfection. Cell viability was evalu-
ated 48 h later (72 h post-transfection) by MTT reduction 
assay. Cytotoxicity of all three drugs, Docetaxel, Stau-
rosporine and Rapamycin were equally increased in both 
DU145 and PC-3 cells, indicating chemo-sensitization was 
not likely depended on the mechanism of cytotoxic drug 
activity but due to alteration in cell survival mechanism 
caused by IL-8 depletion. Results shown are Mean ± SEM 
from three independent experiments, normalized with 
respect to samples with or without drug treatment. Note: 
All cytotoxicity data are normalized with respect to the 
reduction in cell viability due to IL-8siRNA transfection. The 
cytotoxicity was significantly higher (p < 0.04) at all concen-
trations of Docetaxel, and Rapamycin in PC-3 and DU145 
cells, with Staurosporine in DU145 cells and at highest con-
centration tested in for all drugs in both cell lines. We ana-
lyzed the cytotoxicity data by non-linear regression and 
tested the mean survival values by t-test.Page 10 of 15
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knockdown of IL-8 expression caused a significant inhibi-
tion of NF-kB activity and reduction in AKT phosphoryla-
tion (Fig. 4A and 4B). This corroborates our previous
studies that suggested forced expression of IL-8 in andro-
gen-sensitive cells causes constitutive activation of NF-kB
(p65/rel) [21]. Constitutive IL-8 production activates AKT
phosphorylation, but inhibition of AKT phosphorylation
(by PI3Kinase inhibitor) did not prevent IL-8-mediated
NF-kB activity, suggesting, IL-8 directly regulates NF-kB
activation in AIPC cells, independent of AKT-mediated
NF-kB activation [21].
We found that depletion of IL-8 causes a significant reduc-
tion in VEGF transcription and protein levels (Fig. 4C).
This result was anticipated, as shown previously, CXCR2,
the co-receptor of IL-8 stimulates VEGF transcription via
G-protein mediated signaling [44]. Reductions in VEGF
secretion and microvessel density have been reported ear-
lier, in IL-8 reduced PC-3 tumors by IL-8 antisense trans-
fection [22], and in other tumor systems [45].
We observed a significant decrease in invasive activity of
PC-3 cells upon IL-8 depletion, as we had earlier observed,
IL-8 up-regulation increasing the invasive potential of
LNCaP and LAPC-4 cells, which are non-invasive in vitro
[21]. Matrigel invasion involves both proteolytic activity
by Type IV collagenase and chemotactic motility toward
growth factors, present in the serum-containing medium
at the bottom well of the chemotactic chamber. The role
and mechanism of IL-8 as a chemokine has been well
established, and so is an association between autocrine IL-
8 production and increase in invasive enzymes, such as
MMP-2 or MMP-9 [21,23]. Since the invasive activity was
reduced by >48%, IL-8 appears to be a predominant
chemokine in enabling chemo-invasive potential in AIPC
cells.
We found increased spontaneous apoptosis in IL-8
depleted cells. This may be associated with simultaneous
reduction of survival factors, cell cycle arrest, and
increased levels of pro-apoptotic proteins, such as BAX. In
addition, decrease in NF-kB activity may contribute a mul-
titude of signaling networks with overall shift toward
apoptosis. The NF-kB targeted gene includes inhibitor of
apoptosis protein and the BCL-2 family of proteins [46-
48]. Many of these pathways are involved in tumor
growth, angiogenesis, metastasis, and resistance to chem-
otherapy in prostate and other tumors. BCL-2 expression
is lower in localized prostate cancers compared with hor-
mone refractory prostate cancer [49,50]. Over-expression
of BCL-2 is one of many mechanisms that may enable
prostate cancer cells to survive in an androgen-deprived
environment [51,52]. The mechanism of over-expression
of BCL-2 is largely undefined for AIPC. Previous study by
Karl et al., [53] showed a link between BCL-2 and IL-8 in
dermal microvessel endothelial cells, where over-expres-
sion of BCL-2 leads to increased secretion of IL-8, which
in turn promoted angiogenesis. Wilson et al., [43]
reported that some chemotherapy drugs, such as Oxalopl-
atin induce IL-8, this up-regulation leads to CXCR-2 medi-
ated induction of BCL-2 and survivin expression.
Furthermore, blocking of either CXCR2 or NF-kB activa-
tion down regulates BCL-2. Our results extend this obser-
vation to both anti-apoptotic proteins and pro-apoptotic
proteins, BAX and BAD, with one difference. We did not
use external IL-8 stimulation, but decreased the endog-
enous level that resulted in both transcriptional inhibi-
tion of BCL-2 and BCL-2 protein stability (Fig. 5A–D).
Collectively, these finding suggest that IL-8 is the major
regulator of chemoresistance in aggressive, AIPC cells and
likely in patients with metastatic CaP. Indeed, IL-8 is prog-
nostic marker for aggressive disease [41,54] and elevated
levels of IL-8 in the plasma of patients with advanced
(AIPC) disease have been reported [55].
Targeted therapy offers a unique opportunity to inhibit
the activity of specific gene that is critical for growth and
metastasis. It is significant to note that knockdown of IL-
8 expression in PC-3 and DU145 cells with IL-8 siRNA sig-
nificantly enhanced the chemotherapy responses as
increased cytotoxicity. These observations might open a
new opportunity to enhance the therapeutic efficacy of
antitumor drugs: docetaxel, Staurosporine and rapamy-
cin, in refractory tumors or in metastatic stage of AIPC.
The combination of anti-IL8 and approved chemotherapy
protocols may allow, not only reduction in the dose of the
drugs, but also increased efficacy.
Conclusion
We provide extensive evidence to demonstrate IL-8 medi-
ated regulation of complex intracellular molecular signal-
ing that leads to aggressive tumor cell behavior and
increased survival during response to chemotherapy drug
toxicity. We provide direct evidence for the control of anti-
apoptotic protein expression by IL-8, both at the tran-
scription and protein stability. The suppression of IL-8
using RNAi or specific cell permeable inhibitors of IL-8 or
its receptors, may help sensitize AIPC to a wide variety of
chemotherapeutic agents and might increase the survival
of patients with end-stage disease.
Materials and methods
Reagents
Characterized fetal bovine serum was from Atlanta Bio-
logicals (Atlanta, GA), Cell culture grade gentamicin, cul-
ture media, and transfection reagents were all from Gibco-
Invitrogen (Carlsbad, CA). Both non-targeted, random
sequence small interfering RNA (siRNA) and On-Target
anti-IL-8siRNA were purchased from Dharmacon (Chi-Page 11 of 15
(page number not for citation purposes)
Molecular Cancer 2009, 8:57 http://www.molecular-cancer.com/content/8/1/57cago, IL). The Smartpool On-Target siRNA were an equal
mix of 4-siRNA species designed to hybridize and destroy
human IL-8 mRNA (Gen Bank Accession No.
NM_000584). These siRNAs were sequence verified to be
specific to IL-8, thus eliminating the off-target effects.
Dual-Glo luciferase assay kit was from Promega Corpora-
tion (Madison, WI). All reagents, other than primer sets,
for real time, quantitative RT-PCR (Q-PCR) were from
BioRad labs (Richmond, CA). All DNA primer sets for
PCR and Q-RTPCR were custom designed and synthesized
from Sigma-Genosys. Various primary and secondary
antibodies were purchased from Cell signaling or Sigma-
Aldrich, unless otherwise indicated.
Cells and culture conditions
PC-3, LNCaP and Du145 cells were purchased from Amer-
ican Type Culture Collection, (ATCC, Manassas, VA) and
were maintained in vitro in RPMI medium supplemented
with 10% fetal bovine serum and gentamicin (2 μg/ml)
and maintained at 5% CO2/37°C incubator.
siRNA transfection and Real time PCR
The transient transfection of siRNA was performed with
Dhramfect-2 transfection protocol (Dharmacon) with
modifications. Briefly, the day before transfection, the 1 ×
104 cells were plated in antibiotic free-RPMI medium with
10% FBS. Both on-target siRNA and Control siRNA were
used at the same concentration in all experiments. Total
RNA was isolated using RNAeasy mini kit (Qiagen Inc.,
Santa Clara, CA) following 48–72 hr transfection and
used for reverse transcription real time PCR (qPCR) using
the Bio-Rad iCycler iQ real time PCR system (Bio-Rad,
Hercules, CA) with the gene specific primers. Primers
sequences for IL-8-F 5'-ATGACTTCCAAGCTGGCCGT-
GCT-3'; IL-8-R 5'-TCTCAGCCCTCTTCAAAAACTTCT-3',




3-phosphate dehydrogenase (G3PDH) were G3PDH-F
5'TCCTCTGACTTCAACAGCGACAC-3'; G3PDH-R5'-
CACCCTGTTGCTGTAGCCAAATTC-3'. The Q-PCR reac-
tion was carried out using 2 μl of undiluted cDNA follow-
ing the RT-reaction, and 0.225 μM of primer sets, and 2 ×
SYBR green master mix (BioRad). Regular PCR protocol
was employed to time resolved PCR with an annealing
temperature of 55°C for all primers annealed. Amplicon
formation with each primer set was monitored with melt
curve analysis. Gene expression was quantified relative to
that of the housekeeping gene, cDNA for glyceraldehyde
3-phosphate dehydrogenase (G3PDH) as internal con-
trol. The threshold cycle (Ct) of each sample was deter-
mined by using SYBR green fluorescence of labled strands,
and the relative level of expression (Fold difference, FD)
was calculated as 1-(2ΔCt), where ΔCt = (test Ct - GAPDH
Ct); data expressed as (1/FD) × 100, for easy to read inte-
ger numbers [21].
Cell proliferation and drug sensitivity assay
Proliferation status of PC-3 and DU145 cultures, 48 h
after siRNA transfection, were assessed using a colorimet-
ric thiozolyl blue [3(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) reduction assay or
by direct cell counts, as described before [56]. Drug
induced toxicity was determined following incubation
with the indicated drug for 48 h with the control and
siRNA transfected cultures. Cytotoxicity was normalized
to that obtained with control siRNA transfected without
drug-treated cultures.
Determination of protein levels by immunoblotting 
(Western blotting)
Whole cell lysates prepared from treated cultures were
fractionated on SDS-ployacrylamide gel electrophoresis
and blotted on PVDF membranes (Millipore Inc., MA).
Following blotting membrane was probed with antibod-
ies specific for proteins of interest. Antibodies bound to
target proteins were made visible by treating the mem-
brane with enhanced chemoluminescence reaction using
a kit (ECL plus kit, Amersham Pharmacia Biotech, Piscata-
way, NJ, USA) and exposing the membrane to X-ray film.
Appropriate positive and negative control proteins, size
markers and control cell lysates were loaded in parallel
lanes to determine specificity of antibodies and minimize
gel-to-gel variation. The blots were re-probed with anti-
body to β-actin to confirm equal loading of the solubi-
lized samples. The intensity of specific protein bands were
compared following digitization using a program (Kodak
1-D Gel analysis system, Kodak Corp, Rochester, NY).
Quantitation of secreted proteins by ELISA
We assayed IL-8 and VEGF in the conditioned medium of
various transfectants by enzyme immunoassays using
commercial ELISA kits (Research Diagnostics Inc; R&D
Systems) and the levels were normalized to cell number.
Absolute levels of antigens, IL-8 and VEGF secreted by cul-
tures were determined using the assay standards provided
in the assay kits. Data are presented as Mean ± SEM from
three separate experiments.
Cell cycle phase-fractionation and estimation of cell 
cycles-phase fractions
We used flow cytometry to determine the DNA content of
individual cells at 48 h following transfection with C-
siRNA and IL-8 siRNA as described before [56]. Briefly, we
harvested transfected or drug-treated cultures directly in a
hypotonic solution containing Propidium iodide (50 μg/
ml) and 0.04% NP-40 and the resulting suspension of
nuclei was analyzed for DNA content using a flow cytom-
eter (Beckman-Coulter Xcel, Miami, FL), in which 5 × 104Page 12 of 15
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into DNA histograms and individual cell-cycle phase-frac-
tion was quantified using an analysis software (ModFit,
Verity software Inc, Topsham, ME) [57].
Determination of invasive activity
Invasive potential of transfected cells were determined by
matrigel invasion assay as described before [21]. Briefly,
cells were harvested 48 h after transfection with C-siRNA
or IL-8siRNA using a hypotonic Cell stripper solution
(Sigma-Aldrich) and suspended at 1 × 106 cells/ml in
serum-free RPMI medium. The cell suspension (0.4 ml)
was then placed on the top chamber of the Costar Tran-
swell chamber plate previously coated with a basement
membrane extract (Matrigel, Collaborative Research/BD
Biosciences Inc, Bedford, MA). The lower compartment of
Transwell was filled with 10% FBS in RPMI medium as
chemo attractant or RPMI+ ITS medium as a control. Per-
cent of invaded cells was estimated after 24 h incubation
at 37°C in 5% CO2, using the MTT assay. Percent of cell
population invading the Matrigel was calculated as a ratio
of the optical density of cells in the top and bottom cham-
bers [56]. Percent invaded cells = OD of the bottom wells/
Total OD × 100. Experiment was repeated for two more
times with independent transfections.
Reporter assays
We assayed the activities of NF-kB using a reporter gene
construct, as described before [21]. We plated 1 × 104
cells/well in 96-well plate and co-transfected with siRNA
for IL-8 or C-siRNA, and 5 × NFKB-LUC (Stratagene/Agi-
lent Technologies, San Diego, CA). Duplicate cultures
treated identically, but co-transfected with TK Renilla
plasmid (50 ng/ml) were used as internal control. Lumi-
nescence activity was measured using the Dual-Glo™ Luci-
ferase Assay kit (Promega) as instructed. The activity of
both the firefly and the Renilla Luciferase was determined
in triplicate. Reporter activity was normalized to TK-
Renilla luminescence and expressed in arbitrary units.
Statistical analyses
All data reported in this report were generated using in
vitro assays. The significance of the observation was esti-
mated by Student's t-test, using data from at least three
independent replicates, or by linear and non linear regres-
sion analysis, as indicated in each figure, except that of
western blots, where the normalized band density was
used to determine the significance. The observation was
deemed significant if the probability of accepting null
hypothesis is ≤ 0.05 (indicated by * in the Figures).
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